(-0.14%) 5 140.00 points
(-0.11%) 38 516 points
(-0.06%) 17 894 points
(-0.29%) $82.39
(1.67%) $2.06
(-0.89%) $2 336.80
(-1.95%) $27.12
(-0.52%) $956.50
(0.19%) $0.934
(0.47%) $11.03
(0.19%) $0.798
(-0.11%) $93.20
Live Chart Being Loaded With Signals
Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of oncology, metabolic, autoimmune, neurologic, and infectious diseases in the People's Republic of China...
Stats | |
---|---|
本日の出来高 | 6.91M |
平均出来高 | 6.39M |
時価総額 | 23.95B |
EPS | CNY0 ( 2023-10-26 ) |
次の収益日 | ( CNY0 ) 2024-06-28 |
Last Dividend | CNY0 ( N/A ) |
Next Dividend | CNY0 ( N/A ) |
P/E | -12.50 |
ATR14 | CNY0.106 (0.37%) |
ボリューム 相関
Shanghai Junshi 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Shanghai Junshi 相関 - 通貨/商品
Shanghai Junshi 財務諸表
Annual | 2023 |
収益: | CNY1.48B |
総利益: | CNY698.62M (47.11 %) |
EPS: | CNY-2.32 |
FY | 2023 |
収益: | CNY1.48B |
総利益: | CNY698.62M (47.11 %) |
EPS: | CNY-2.32 |
FY | 2022 |
収益: | CNY1.45B |
総利益: | CNY927.21M (63.79 %) |
EPS: | CNY-2.81 |
FY | 2021 |
収益: | CNY4.02B |
総利益: | CNY2.77B (68.74 %) |
EPS: | CNY-0.871 |
Financial Reports:
No articles found.
Shanghai Junshi
Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of oncology, metabolic, autoimmune, neurologic, and infectious diseases in the People's Republic of China. The company offers JS001, a recombinant humanized anti-PD-1 monoclonal antibody under the trade name of TUOYI for the indication of melanoma, mucosal melanoma, soft tissue sarcoma, nasopharyngeal carcinoma, urothelial carcinoma, non-small cell lung carcinoma, triple negative breast carcinoma, esophageal squamous cell carcinoma, and hepatocellular carcinoma. It is also developing UBP1211, a biosimilar of Humira for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriasis; JS002, a recombinant humanized anti-PCSK9 monoclonal antibody for treating hyperlipidemia; UBP1213, a recombinant humanized anti-BLyS monoclonal antibody for injection. In addition, the company is developing JS501, a biosimilar of Avastin; and JS003, a recombinant humanized anti-PD-L1 monoclonal antibody for injection; JS101, a pan-CDK inhibitor; TAB004/JS004, a recombinant humanized anti-BTLA monoclonal antibody for injection; and JS005, a recombinant humanized anti-IL-17A monoclonal antibody for injection. It has an agreement with Eli Lilly and Company to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, the disease caused by the SARS-CoV-2 novel coronavirus as well as Coherus Biosciences, Inc. for the development and commercialization of toripalimab, Junshi Biosciences' anti-PD-1 antibody. Shanghai Junshi Biosciences Co., Ltd. was founded in 2012 and is headquartered in Shanghai, People's Republic of China.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。